In small study, CAR-Ttherapy pushes lupus into remission nejm NatureMedicine
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Consort Flow Diagram. Flow diagram showing eligibility criteria for patients with systemic lupus erythematosus to receive treatment with CD19 chimeric antigen receptor T cells. Of the 14 SLE patients screened, 2 had no active involvement of the inner organs, 4 had not received all treatments approved for SLE and 1 patient did not understand the procedure.
Immunophenotyping of T cells expressing the chimeric antigen receptor and those not expressing the CAR . Peripheral blood mononuclear cells from the 5 Systemic Lupus Erythematosus patients that received CAR T cells were analyzed using FACS analysis. T cells were analyzed 3, 9, 16, 23, 30 and 60 days after CAR T cell treatment. Stainings distinguished naïve T cells , central memory cells , effector memory T cells and effector memory T cells re-expressing CD45RA .
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia | Journal of Clinical OncologyPURPOSE The FMS-related tyrosine kinase 3 (FLT3) inhibitor gilteritinib is standard therapy for relapsed/refractory FLT3-mutated (FLT3mut) acute myeloid leukemia (AML) but seldom reduces FLT3mut burden or induces sustained efficacy. Gilteritinib combines synergistically with the BCL-2 inhibitor venetoclax in preclinical models of FLT3mut AML. METHODS This phase Ib open-label, dose-escalation/dose-expansion study (ClinicalTrials.gov identifier: NCT03625505) enrolled patients with FLT3 wild-type and FLT3mut (escalation) or FLT3mut (expansion) relapsed/refractory AML. Patients received 400 mg oral venetoclax once daily and 80 mg or 120 mg oral gilteritinib once daily. The primary objectives were safety, identification of the recommended phase II dose, and the modified composite complete response (mCRc) rate (complete response [CR] + CR with incomplete blood count recovery + CR with incomplete platelet recovery + morphologic leukemia-free state) using ADMIRAL phase III–defined response criteria. RESULTS Sixty-one patients were enrolled (n=56 FLT3mut); 64% (n=36 of 56) of FLT3mut patients had received prior FLT3 inhibitor therapy. The recommended phase II dose was 400 mg venetoclax once daily and 120 mg gilteritinib once daily. The most common grade 3/4 adverse events were cytopenias (n=49; 80%). Adverse events prompted venetoclax and gilteritinib dose interruptions in 51% and 48%, respectively. The mCRc rate for FLT3mut patients was 75% (CR, 18%; CR with incomplete blood count recovery, 4%; CR with incomplete platelet recovery, 18%; and morphologic leukemia-free state, 36%) and was similar among patients with or without prior FLT3 inhibitor therapy (80% v 67%, respectively). The median follow-up was 17.5 months. The median time to response was 0.9 months, and the median remission duration was 4.9 months (95% CI, 3.4 to 6.6). FLT3 molecular response (| 10−2) was achieved in 60% of evaluable mCRc patients (n=15 of 25). The median overall survival for FLT3mut patients was
Read more »
Transit-amplifying cells control R-spondins in the mouse crypt to modulate intestinal stem cell proliferationChaves-Pérez et al. report mechanisms of regulation of ISC proliferation following injury. The death of transit-amplifying cells triggers inflammation that redu
Read more »
GABAergic CA1 neurons are more stable following context changes than glutamatergic cells - Scientific ReportsScientific Reports - GABAergic CA1 neurons are more stable following context changes than glutamatergic cells
Read more »
How Long Your Walks Outside Need To Be For A Mental Health BoostA new study reveals how many minutes spent in nature actually improve our mood.
Read more »
Six new Telford sites set to be designated Local Nature ReservesSix new nature reserves could be designated in Telford under plans to be discussed by councillors.
Read more »
Sainz hits out at 100kg weight increase for Audi's Dakar contenderCarlos Sainz has expressed his frustration at the minimum weight of T1U cars being raised by 100kg for the 2023 Dakar Rally, saying rules are hurting electric cars such as the Audi.
Read more »